95522-45-5

95522-45-5 structure
95522-45-5 structure
  • Name: 2-(chloromethyl)oxirane,2-methyl-1H-imidazole
  • Chemical Name: 2-(chloromethyl)oxirane,2-methyl-1H-imidazole
  • CAS Number: 95522-45-5
  • Molecular Formula: C7H11ClN2O
  • Molecular Weight: 174.62800
  • Catalog: Research Areas Metabolic Disease
  • Create Date: 2018-06-16 00:36:38
  • Modify Date: 2024-01-09 20:25:18
  • Colestilan (MCI-196) is a non-absorbed, non-calcium-based phosphate binder and is also a non-metallic, anion exchange resin. Colestilan is orally active and can be used for hypercholesterolaemia research[1][2].

Name 2-(chloromethyl)oxirane,2-methyl-1H-imidazole
Synonyms Colestilan
Epichlorohydrin-2-methylimidazole copolymer
Colestimide
MCI 196
Cholebine
Description Colestilan (MCI-196) is a non-absorbed, non-calcium-based phosphate binder and is also a non-metallic, anion exchange resin. Colestilan is orally active and can be used for hypercholesterolaemia research[1][2].
Related Catalog
In Vitro Colestilan (MCI-196) decreases cholesterol levels by bile acid adsorption through the gastrointestinal tract[2]. Colestilan (1 g) binds 2.52 mmol of phosphate at 2–4 mM phosphate concentration and pH7.2 in vitro[2].
In Vivo Colestilan (MCI-196) (0.125 or 0.5 g content per 15 g of the feed; p.o.; 14 days) decreases blood phosphate and urinary phosphorus excretion in rats[3]. Colestilan is able to improve hyperphosphataemia in rats with renal failure induced by adenine administration for 4 weeks[1]. Animal Model: 6-week old Wistar male rats[3] Dosage: 0.125 or 0.5 g content per 15 g of the feed Administration: Oral in feed, 14 days Result: Dose dependently decreased blood phosphate and urinary phosphate excretion.
References

[1]. Locatelli F, et al. Effect of MCI-196 on serum phosphate and cholesterol levels in haemodialysis patients with hyperphosphataemia: a double-blind, randomized, placebo-controlled study. Nephrol Dial Transplant. 2010 Feb;25(2):574-81.

[2]. Kurihara S, et al. Effect of MCI-196 (colestilan) as a phosphate binder on hyperphosphataemia in aemodialysis patients: a double-blind, placebo-controlled, short-term trial. Nephrol Dial Transplant. 2005 Feb;20(2):424-30.

[3]. MATSUKA MASAYUKI, et al. Use of anion exchange resins for the manufacture of a medicament for the treatment of hyperphosphatemia. Patent EP0793960.

Molecular Formula C7H11ClN2O
Molecular Weight 174.62800
Exact Mass 174.05600
PSA 41.21000
LogP 1.34210